Khalil Ghasemi Falavarjani 1 , Srinivas R Sadda 2 Show Affiliations »
Abstract
BACKGROUND: The preferred approach for the treatment of neovascular age-related macular degeneration (AMD) is frequent intravitreal injections of the anti-vascular endothelial growth factor (VEGF) agents. However, considering the limitations of current anti-VEGF approaches, including the need for frequent injections, inadequate response in some patients, and a relatively short duration of effect, several new therapeutic modalities are under evaluation. METHODS: A comprehensive review of the literature was performed on the new treatment modalities for neovascular AMD, and the relevant studies were discussed. RESULTS: The treatment modalities for neovascular AMD include new anti-VEGF drugs, new drug delivery systems and new targets in the pathogenic cascade of choroidal neovascularization. These new modalities are in different phases of clinical development. CONCLUSION: The results of the completed studies reporting the new therapeutic modalities for neovascular AMD thus far are promising. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
BACKGROUND: The preferred approach for the treatment of neovascular age-related macular degeneration (AMD ) is frequent intravitreal injections of the anti-vascular endothelial growth factor (VEGF ) agents. However, considering the limitations of current anti-VEGF approaches, including the need for frequent injections, inadequate response in some patients , and a relatively short duration of effect, several new therapeutic modalities are under evaluation. METHODS: A comprehensive review of the literature was performed on the new treatment modalities for neovascular AMD , and the relevant studies were discussed. RESULTS: The treatment modalities for neovascular AMD include new anti-VEGF drugs, new drug delivery systems and new targets in the pathogenic cascade of choroidal neovascularization. These new modalities are in different phases of clinical development. CONCLUSION: The results of the completed studies reporting the new therapeutic modalities for neovascular AMD thus far are promising. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Entities: Disease
Gene
Species
Keywords:
Aflibercept; age-related macular degeneration; choroidal neovascularization; conbercept; designed ankyrin repeat proteins; encapsulatedzzm321990cell technology; pharmacotherapy; platelet derived growth factor; ranibizumab; squalamine; vascular endothelial growthzzm321990factor
Mesh： See more »
Substances： See more »
Year: 2017
PMID： 27981904 DOI： 10.2174/1381612822666161216121105
Source DB: PubMed Journal: Curr Pharm Des ISSN： 1381-6128 Impact factor: 3.116